Abstract-The aim of this paper is to introduce the recent research and commercial developments in minimally and noninvasive blood glucose monitoring techniques.
INTRODUCTION
Diabetes is one of the largest global health emergencies of the 21st century [1] . More than 1 in 11 adults (415 million) were found to have diabetes in 2015 and this number is rapidly rising, being estimated to reach almost 1 in 10 adults (642 million) by 2040. At least 673 billion USD in health expenditure were spent on the care of diabetes related complications, including direct and indirect costs. In the United Kingdom, 17% of the total spending by the National Health Service is estimated to be spent on diabetes in 2035/2036 [2] [3] . There are significant amount of ongoing researches but there is no known cure for diabetes yet.
For people with diabetes, the most important requirement is a tight control of the blood glucose (BG) level to minimize the dwelling time in high (>11.1 mmol/L) or low (<3.9 mmol/L) BG levels. The most effective method to achieve tight control is to self-monitor the BG levels as frequent as possible. Fingerprick test by using test strips and a glucose meter is the most common and widely available method for its reasonable accuracy and precision, convenience, and its ability to provide real-time plasma glucose levels on demand. Wide range of commercial glucose meters and reagent test strips are available including Abbott's Freestyle line, Ascensia Diabetes Care's (formerly Bayer) Contour line, GlucoRX's Nexus line, LifeScan's OneTouch line, and Roche's Accu-Check line, to name a few. However, a number of factors discourage the use of this method, especially the pain due to repeated finger-prick with lancets to draw blood sample, fear of infection during the pricking process, cost of test accessories, and the invasiveness to their daily life. One of the critical disadvantages of the fingerprick test is that it is only able to provide a discrete snapshot of the continuous change of BG levels during the day. Therefore one might miss important hyperglycemic and hypoglycemic events between the discrete fingerprick tests.
To overcome this issue, continuous glucose monitoring (CGM) methods have been developed. The most common method is to have a flexible needle placed under the skin with a data transmitting device sitting on the skin, which continuously monitors interstitial fluid (ISF) glucose levels. Among several techniques, an enzyme-based electrochemical sensing method is adopted for commercial products for its specificity and decent accuracy, and small footprint required. This technique has contributed in improving the quality of life of people with diabetes by reducing the required number of fingerprick tests and providing the continuous trace of fluctuation of glucose levels. With the rapid development of circuit integration technologies, CGMs have made a great leap and are becoming more and more popular. Still, the flexible subcuraneous needle has to be inserted into the skin by an invasive guide needle and therefore same disadvantages still exist regarding the invasiveness of the technique, including the pain and fear of infection and the replacement of the sensor every few weeks. Therefore the demand and expection for a truly non-invasive blood glucose monitor is growing higher and higher.
II. RESEARCH PUBLICATIONS
A number of minimally invasive and purely non-invasive blood glucose monitoring devices have been reported based on a wide range of interesting technologies [4] - [7] . In [8] , ultrasound was facilitated to enhance the outward transport of glucose from ISF through skin to overcome the fundamental problem of obtaining sufficient amount of samples in a transdermal approach (sonophoresis). A small implantable fluorescence-based sensor combined with a body-worn data transmitter was proposed in [9] to increase the sensor lifetime up to 6 months comparing to a few weeks' lifetime of typical subcutaneous sensors. A watch-type transdermal sensor using microneedles to extract ISF glucose through skin [10] , an ultrasound and multi-sensor-based ear-clip type non-invasive sensor for discrete measurement [11] , a contact-lens-type noninvasive sensor measuring glucose concentration in tears [12] , an occlusion spectroscopy-based sensor measuring blood flow [13] , and electrochemical subcutaneous continuous monitoring sensors [14] have been reported. A sensor based on the combination of impedance (10 to 76 kHz range) and multiwavelength (850nm, 950nm, 1300nm) near infra-red (NIR) spectroscopy with a dedicated integrated circuit [15] and a technique measuring the refraction of visible laser light to overcome the signal to noise ratio issue related to NIR spectroscopy [16] were also reported. Wearable sensors capable of measuring glucose concentration through saliva and sweat [17] [18] , and a benchtop system capable of estimating glucose level through breath have been published [19] [20] .
In the RF and microwave area, the resonant and nonresonant near-field monitoring technique has been widely used for its non-invasive characteristic and high sensitivity. A broadband coplanar waveguide sensor with the combination of microfluidic system was proposed in [21] 
was proposed for non-invasive BG measurement but with limited dataset from 5 subjects [22] . A reflection and transmission based broadband measurement techniques using microstrip line [23] and microstrip patch/slot antenna-based sensor [24] can be found, but without human clinical trial results. Millimeter-wave waveguide transmission measurement system and its clinical trial results on rats [25] have been reported using microwave techniques. The basis of these is that the complex dielectric constant changes with the presence and fluctuation of blood glucose concentration in the water/glucose system [26] 
III. COMMERCIAL DEVELOPMENTS
There is no truly non-invasive and continuous blood glucose monitoring sensor availabe in the self-monitoring of BG market yet. It is extremely difficult challenge to be able to detect only a small fluctuation in BG concentration through a very lossy human tissue, with endogenic chemical interference, with physiological variation between subjects, during a normal daily life (environmental variation and movement) to name a few. On top of that, accuracy and precision requirement by the medical regulation and standard (e.g., ISO:15197:2013) is ever increasing. In its current version, ISO:15197 requires that 95% of BG test results should meet the following key requirements: -Within ± 15 mg/dL (or 0.83 mmol/L) of laboratory results at concentrations under 100 mg/dL (or 5.6 mmol/L) -Within ± 15% of laboratory results at concentrations of 100 mg/dL (or 5.6 mmol/L) or more.
-For type 1 diabetes, 99% of readings must fall within zones A and B of the Consensus Error Grid However there are several candidates that provide near-noninvasive performance, and some examples are now discussed.
GlucoTrack model DF-F (by Integrity Applications) is a CE-Mark approved device, which consists of an ear clip type sensor and a main display unit. It is known to use ultrasound, electromagnetic and temperature measurements with a unique algorithm to weight each measurement and calculate the weighted average of the three readings [11] . Technically this device is truly non-invasive but in their current version only discrete readings are available and the accuracy is not as good as enzyme-based subcutaneous sensors. The ear clip must be replaced every 6 months for reliable measurements. Clinical trial results show that 97.3% of the readings fall within Zone A and B in the Clarke Error Grid [11] .
SugarBEAT (by Nemaura Medical) is a patch type sensor, known to use the technique called reverse iontophoresis [30] . It passes a mild, non-perceptible electric current across the skin to draw a small amount of glucose molecules from the ISF into a patch placed on the skin. The recent clinical trial consisted of 81 paired data points, with a single finger prick calibration, and glucose range between 70-400 mg/dl. The results indicated a mean absolute relative difference (MARD) of 14.05%, and 75% of the data in Zone A, and over 98% of the data in Zones A and B of the Clarke Error grid. The patch lasts one day and needs one finger prick calibration a day. The device is aimed to be launched in 2017.
NovioSense is a small and flexible spring like device measuring less than 2 cm in length and 1.5mm in diameter [31] . The whole device is coated with a soft hydrogel layer. The flexible form factor allows the device to bend to conform to the surface of the lower eye lid where the sensor is placed. This device uses a glucose oxidase electrochemical sensor attached to a hollow coil coated in hydrophilic gel allowing the sensor to follow the shape of the eye. It utilizes state of the art low-power and highly sensitive ASIC technology developed by the Fraunhofer Institute of Microelectronic Circuits and Systems together with NovioSense. The device can measure minute changes in glucose levels in the tears that are representative of blood glucose levels. Through animal studies, 92% of data were in Zone A+B region of the Clarke Error Grid. The device is aimed to be launched in 2018.
One critical challenge of measuring glucose concentration through ISF is the dispersion delay. Dispersion delay is the time for plasma glucose to disperse from blood vessel to ISF. This can vary from 5 to 45 minutes between subjects, and can even vary for a specific subject on a different day. Tear, saliva, or sweat have even longer dispersion delay than ISF, so they are not suitable for type 1 diabetes.
The Eversense Sensor is designed to be implanted subcutaneously in the upper arm [32] . No part of the sensor protrudes out of the skin surface. Encased in a biocompatible material, the sensor utilizes a patented fluorescent, glucose indicating polymer technology to measure glucose in the ISF. The measurement is then relayed to the smart transmitter. The measurement and display of glucose values is done automatically, without the need for user intervention. Senseonics' Eversense CGM has shown exceptional results in a clinical study: 8.8%. The PRECISE II clinical study enrolled 90 adults with diabetes over 90 days of continuous glucose sensor wear. The study collected over 16,000 comparative data points with over 2 million glucose readings. Although simple, this device requires a surgical operation. by scanning a subcutaneous sensor on their arm measuring ISF glucose rather than taking finger-prick blood glucose tests [33] . The system is able to provide graphical trends of sugar levels which provides much more data than blood glucose tests. Unlike CGMs, the Libre is not able to alert the user of high or low blood sugar until the user actively scans. However, the trendline shows whether sugar levels are heading up or down, and how quickly, which alarms the user of the onset of hypoglycemia. The FreeStyle Libre system has a proven accuracy of 11.4% MARD compared to a reference BG concentration. It is clinically proven to be accurate, stable and consistent over 14 days without the need for finger prick calibration. To be able to insert the flexible subcutaneous needle, an insertion device with a big guide needle must be used.
IV. CONCLUSION
Diabetes prevalence is on the rapid rise worldwide and is a crisis facing 21 st century society. Therefore, the selfmonitoring blood glucose device market is exponentially growing. A variety of techniques to achieve minimally invasive and truly non-invasive blood glucose monitoring have been reviewed, including RF, microwave, mm-wave, and even optic wavelength, with highly promising results.
